{"schema_version":"secwatch.filing_event.v1","accession":"0000914475-22-000021","form_type":"8-K","ticker":"NBIX","cik":"0000914475","company_name":"NEUROCRINE BIOSCIENCES INC","filed_at":"2022-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:04:04.367296+00:00","generated_at":"2026-06-26T01:07:37.052080+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Neurocrine Q1: INGREZZA sales $303M (+32% YoY), GAAP EPS $0.14, reaffirms FY guidance","bullets":["Net product sales $303M (+32% YoY); total revenue $310.6M incl $5.6M collaboration revenue.","GAAP net income $13.9M ($0.14 diluted EPS) vs $32.1M ($0.33) in Q1 2021.","Non-GAAP net income $29.7M ($0.30 diluted EPS) vs $48.8M ($0.50) prior year.","Cash and marketable securities $1.2B; reiterates 2022 INGREZZA sales guidance $1.25-$1.35B.","Positive Phase 3 valbenazine data in Huntington chorea; sNDA filing expected H2 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0000914475-22-000021","json":"https://secwatch.observer/filing/0000914475-22-000021.json","markdown":"https://secwatch.observer/filing/0000914475-22-000021.md","text":"https://secwatch.observer/filing/0000914475-22-000021.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/914475/000091447522000021/0000914475-22-000021-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/914475/000091447522000021/nbix-20220504.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T01:07:37.052080+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}